CA3294570A1 - Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation - Google Patents

Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation

Info

Publication number
CA3294570A1
CA3294570A1 CA3294570A CA3294570A CA3294570A1 CA 3294570 A1 CA3294570 A1 CA 3294570A1 CA 3294570 A CA3294570 A CA 3294570A CA 3294570 A CA3294570 A CA 3294570A CA 3294570 A1 CA3294570 A1 CA 3294570A1
Authority
CA
Canada
Prior art keywords
pat
claimtext
claimnumber
effective amount
math
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3294570A
Other languages
English (en)
Inventor
Jeffrey S. Glenn
Edward A. Pham
Original Assignee
Eiger Group International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group International Inc filed Critical Eiger Group International Inc
Priority to CA3178499A priority Critical patent/CA3178499C/en
Publication of CA3294570A1 publication Critical patent/CA3294570A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3294570A 2015-06-30 2016-06-30 Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation Pending CA3294570A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3178499A CA3178499C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30
CA3178499A CA3178499C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3178499A Division CA3178499C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Publications (1)

Publication Number Publication Date
CA3294570A1 true CA3294570A1 (en) 2026-03-02

Family

ID=57609247

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3294570A Pending CA3294570A1 (en) 2015-06-30 2016-06-30 Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation
CA2989634A Active CA2989634C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in prevention or treatment of liver cancer
CA3178499A Active CA3178499C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2989634A Active CA2989634C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in prevention or treatment of liver cancer
CA3178499A Active CA3178499C (en) 2015-06-30 2016-06-30 Use of clemizole, deuterated analogs of clemizole, or clemizole metabolites in treatment of an inflammatory condition

Country Status (14)

Country Link
US (3) US10688083B2 (enExample)
EP (1) EP3317274A4 (enExample)
JP (3) JP7068827B2 (enExample)
KR (3) KR20230129590A (enExample)
CN (2) CN107922404B (enExample)
AU (4) AU2016288699B2 (enExample)
CA (3) CA3294570A1 (enExample)
HK (1) HK1249508A1 (enExample)
IL (4) IL300476B2 (enExample)
MX (3) MX394605B (enExample)
NZ (1) NZ776616A (enExample)
TW (3) TWI771272B (enExample)
WO (1) WO2017004454A1 (enExample)
ZA (2) ZA201708471B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3294570A1 (en) * 2015-06-30 2026-03-02 Eiger Group International, Inc. Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
CA3082591A1 (en) * 2017-11-15 2019-05-23 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用
CN117466821A (zh) * 2023-10-25 2024-01-30 中化医药有限公司 一种盐酸克立咪唑的工艺制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
TW200902047A (en) 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
AU2003219160A1 (en) * 2003-03-12 2004-09-30 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CN1893978A (zh) 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
EP1888033B1 (en) * 2005-06-09 2014-02-19 Meda AB Method and composition for treating inflammatory disorders
MX2008010355A (es) 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
WO2009039248A2 (en) * 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
HUE052510T2 (hu) * 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
CN102548393B (zh) * 2009-07-31 2015-06-03 斯特里克再生医学学院,斯特里克学院事务所 脂肪性肝炎-肝癌模型动物
KR20180036810A (ko) * 2009-08-14 2018-04-09 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
US9415046B2 (en) * 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
EP2818473A4 (en) * 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20130273003A1 (en) * 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
WO2013180149A1 (ja) 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
WO2014031769A2 (en) 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CA3294570A1 (en) * 2015-06-30 2026-03-02 Eiger Group International, Inc. Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation

Also Published As

Publication number Publication date
IL310969A (en) 2024-04-01
WO2017004454A8 (en) 2018-01-25
KR20230129590A (ko) 2023-09-08
JP2024083475A (ja) 2024-06-21
EP3317274A1 (en) 2018-05-09
MX2022008100A (es) 2022-07-11
AU2016288699A1 (en) 2018-01-18
TWI830262B (zh) 2024-01-21
US12090141B2 (en) 2024-09-17
JP7068827B2 (ja) 2022-05-17
MX2017016681A (es) 2018-07-06
US20240398761A1 (en) 2024-12-05
AU2023201397B2 (en) 2024-10-03
KR20180032578A (ko) 2018-03-30
JP2022105149A (ja) 2022-07-12
TW202402283A (zh) 2024-01-16
KR20260077866A (ko) 2026-05-28
US20180200228A1 (en) 2018-07-19
CA2989634A1 (en) 2017-01-05
IL279020B1 (en) 2023-03-01
US20210052553A1 (en) 2021-02-25
IL300476A (en) 2023-04-01
BR112017028601A2 (pt) 2018-08-28
NZ738291A (en) 2021-06-25
IL279020B2 (en) 2023-07-01
AU2024266943A1 (en) 2024-12-19
CN113274386A (zh) 2021-08-20
WO2017004454A1 (en) 2017-01-05
CA3178499C (en) 2026-05-12
ZA202004136B (en) 2025-08-27
IL300476B1 (en) 2024-03-01
CA3178499A1 (en) 2017-01-05
CN107922404B (zh) 2021-06-29
HK1249508A1 (zh) 2018-11-02
TWI881480B (zh) 2025-04-21
CA2989634C (en) 2022-12-06
TW202317103A (zh) 2023-05-01
MX394605B (es) 2025-03-24
TWI771272B (zh) 2022-07-21
EP3317274A4 (en) 2019-05-08
IL279020A (enExample) 2020-12-31
AU2021201234A1 (en) 2021-03-11
CN107922404A (zh) 2018-04-17
AU2023201397A1 (en) 2023-04-06
JP2018519340A (ja) 2018-07-19
JP7810746B2 (ja) 2026-02-03
US10688083B2 (en) 2020-06-23
TW201717941A (zh) 2017-06-01
JP7470151B2 (ja) 2024-04-17
ZA201708471B (en) 2022-05-25
NZ776616A (en) 2024-11-29
MX2023003792A (es) 2023-04-26
IL256233A (en) 2018-02-28
AU2016288699B2 (en) 2020-11-26
IL300476B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
AU2023201397B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
KR20170130615A (ko) (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
EP3458448B1 (en) Fasn inhibitors for use in treating non-alcoholic steatohepatitis
TWI621438B (zh) 異喹啉生物鹼衍生物用於製備促進ａｍｐｋ活性的藥物之用途
KR20180051430A (ko) 8-히드록시 퀴놀린 유도체의 에난티오머 및 그의 합성
CN113214097A (zh) 治疗阿尔茨海默病的化合物
NZ738291B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
BR112017028601B1 (pt) Uso de clemizol
HK40072310A (en) Magl inhibitor, preparation method therefor and use thereof

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20251203

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251203

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260113

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260113

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260116

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260128

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260424

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260427

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260427

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260504

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260514

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260514